Min Shi, M.D., Ph.D., a hematologist and co-director of Mayo Clinic's Flow Cytometry Laboratory, explains recent updates to the B-cell lymphoblastic leukemia minimal residual disease flow cytometry assay. This test is used to identify minimal residual disease in patients with a previously confirmed diagnosis of B-cell lymphoblastic leukemia who have completed chemotherapy, immunotherapy or bone marrow transplantation.

By Samantha Rossi • November 3, 2020

The results are part of a comprehensive study of 16,175 cases performed at Mayo Clinic over an 11-year period.

By Suzanne Ferguson • September 10, 2020

Horatiu Olteanu, M.D., Ph.D., gives an overview of the new T-cell receptor (TCR) β-chain constant region (TRBC1) flow cytometry marker, which is now included in Mayo Clinic Laboratories' routine diagnostic T-cell flow cytometry panel. He discusses when this testing should be ordered, how the addition of TCRBC1 compares to previous testing approaches, and how this marker can assist ordering physicians.

By Alyssa Frank • August 11, 2020

Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.

By Chris Bahnsen • March 10, 2020

Mayo Clinic Laboratories provides evaluation and consultation for the diagnosis and treatment of patients with hereditary and acquired hematologic disorders.

By Samantha Rossi • February 25, 2020

Linda Baughn Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.

By Samantha Rossi • February 7, 2020

In this month’s “Hot Topic,” Curtis Hanson, M.D., will discuss the use of laboratory-based prognostic markers in patients with chronic lymphocytic leukemia (CLL). He will also highlight the importance of molecular analyses for IGHV and TP53 sequencing in these patients.

By MCL Education • August 12, 2019

David Viswanatha, M.D., a hematopathologist and co-director of the molecular hematology and complete genome sequencing laboratories at Mayo Clinic, provides an overview of BCR/ABL1 testing, discusses the best testing methods, NCCN/ELN criteria guidelines, why FISH testing is no longer routinely available at Mayo Clinic, and what test to order at what time for CML patients.

By Alyssa Frank • July 16, 2019

Curtis Hanson, M.D., discusses the importance of detecting immunoglobulin heavy-chain variable region gene (IGHV) when acquiring prognostic and potentially therapeutic information in chronic lymphocytic leukemia (CLL) patients in CAP TODAY.

By Hannah Crawford • June 6, 2019

The current diagnostic tools in a pathologist’s arsenal sometimes cannot provide a clear distinction between primary mediastinal large B-cell lymphoma (one of the few lymphomas more common in younger women) and diffuse large B-cell lymphoma, the most common type of non-Hodgkin’s lymphoma overall.

By Suzanne Ferguson • April 30, 2019

The standard laboratory test to diagnose multiple myeloma dates back to the Eisenhower administration. Research at Mayo Clinic spearheaded by David Murray, M.D., Ph.D. (PATH ’10), and fueled by his experience as an industrial chemist has led to a new assay to screen and diagnose the disease.

By Mayo Clinic Laboratories • April 29, 2019

In this month’s “Hot Topic,” Rajiv Pruthi, M.B.B.S., will discuss different types of hemophilia along with their pathologic basis. He will also cover various types of factor assays such as one stage and chromogenic factor assays for diagnosis and their role in management of hemophilia.

By MCL Education • March 28, 2019

This week’s Research Roundup highlights an assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients and several other research articles by Mayo Clinic physicians and scientists.

By Alyssa Frank • March 11, 2019